UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 416

Sortiert nach

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

The New England journal of medicine, 2010-01, Vol.362 (2), p.118-128

2010

Volltextzugriff (PDF)

Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene

Human molecular genetics, 2008-07, Vol.17 (13), p.1938-1945

2008

Volltextzugriff (PDF)

‘I should have taken that further’ – missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed‐methods study

Health expectations : an international journal of public participation in health care and health policy, 2016-10, Vol.19 (5), p.1121-1137

2016

Volltextzugriff (PDF)

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Journal of investigative dermatology, 2013-02, Vol.133 (2), p.377-385

2013

Volltextzugriff (PDF)

Psoriasis and Treatment: Past, Present and Future Aspects

Acta dermato-venereologica, 2020-01, Vol.100 (3), p.adv00032-80

2020

Volltextzugriff (PDF)

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

2014

Volltextzugriff (PDF)

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology, 2017-03, Vol.76 (3), p.405-417

2017

Volltextzugriff (PDF)

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Journal of investigative dermatology, 2015-11, Vol.135 (11), p.2632-2640

2015

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine

Clinics in dermatology, 2008-09, Vol.26 (5), p.438-447

2008

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Clinical and genetic differences between pustular psoriasis subtypes

Journal of allergy and clinical immunology, 2019-03, Vol.143 (3), p.1021-1026

2019

Volltextzugriff (PDF)

AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking

American journal of human genetics, 2014-05, Vol.94 (5), p.790-797

2014

Volltextzugriff (PDF)

A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented Spots

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1735-1742

2015

Volltextzugriff (PDF)

Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes

Journal of investigative dermatology, 2013-05, Vol.133 (5), p.1366-1369

2013

Volltextzugriff (PDF)

Skin health in older age

Maturitas, 2014-11, Vol.79 (3), p.256-264

2014

Volltextzugriff (PDF)

Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis

Journal of allergy and clinical immunology, 2022-10, Vol.150 (4), p.882-893

2022

Volltextzugriff (PDF)

Peptide location fingerprinting reveals modification‐associated biomarker candidates of ageing in human tissue proteomes

Aging cell, 2021-05, Vol.20 (5), p.e13355-n/a

2021

Volltextzugriff (PDF)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis

Acta dermato-venereologica, 2021-04, Vol.101 (4), p.adv00445-adv00445

2021

Volltextzugriff (PDF)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Dermatology and therapy, 2020-06, Vol.10 (3), p.431-447

2020

Volltextzugriff (PDF)

The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology

Sleep medicine, 2020-08, Vol.72, p.144-149

2020

Volltextzugriff (PDF)

Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits

Journal of clinical medicine, 2020-05, Vol.9 (5), p.1532

2020

Volltextzugriff (PDF)

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis

The Journal of clinical investigation, 2008-09, Vol.118 (9), p.3151-3159

2008

Volltextzugriff (PDF)

Prevalence of Atrophic and Hypertrophic Skin Ageing Phenotypes: A UK-based Observational Study

Acta dermato-venereologica, 2020-12, Vol.100 (19), p.adv00347-adv00347

2020

Volltextzugriff (PDF)

Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity

Photochemical & photobiological sciences, 2020-09, Vol.19 (9), p.116-1167

2020

Volltextzugriff (PDF)

1 – 25 von 416

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Englisch
(416)
Japanisch
(48)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene

‘I should have taken that further’ – missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed‐methods study

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

Psoriasis and Treatment: Past, Present and Future Aspects

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Clinical and genetic differences between pustular psoriasis subtypes

AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking

A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented Spots

Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes

Skin health in older age

Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis

Peptide location fingerprinting reveals modification‐associated biomarker candidates of ageing in human tissue proteomes

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology

Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis

Prevalence of Atrophic and Hypertrophic Skin Ageing Phenotypes: A UK-based Observational Study

Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity

Suchergebnisse filtern